AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Pagaya, you need to believe its AI-driven underwriting can keep converting rising network volumes into durable earnings while funding and regulatory risks stay manageable. The latest record volumes and raised GAAP net income guidance appear to strengthen the near term earnings catalyst but do not remove concerns around tighter AI lending oversight or dependence on capital markets for loan funding.
Among the recent updates, Pagaya’s higher full year 2026 outlook stands out, with GAAP net income now guided to US$155 million to US$180 million and network volume to US$12.5 billion to US$13.25 billion. This ties the AI underwriting platform directly to current profitability and funding access, making future changes in ABS demand and regulatory expectations especially important to the story.
Yet behind the stronger guidance, there is a growing regulatory and funding risk that investors should be aware of...
Read the full narrative on Pagaya Technologies (it's free!)
Pagaya Technologies’ narrative projects $2.0 billion revenue and $394.6 million earnings by 2029.
Uncover how Pagaya Technologies' forecasts yield a $28.80 fair value, a 24% upside to its current price.
Some of the lowest analysts were already cautious, assuming revenue would grow to about US$1.9 billion and earnings to roughly US$334 million by 2029, and they worry that increasing regulatory scrutiny on AI in lending could compress margins even as the new results challenge parts of that more pessimistic view.
Explore 9 other fair value estimates on Pagaya Technologies - why the stock might be worth 48% less than the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com